Gain position to utilize existing account management skill set in relationship driven sales
for specialty pharma, biotech or B2B «buy and bill» reimbursement to support sales force.
A tie - up between Takeda and Shire could signal a new era
for specialty pharma dealmaking, say analysts and investors, as interest in the sector intensifies again.
Not exact matches
But the initiative comes with another huge financial prize
for firms that successfully win FDA approval
for these niche therapies: a priority review voucher that can be used to slash the regulatory period
for a different experimental
specialty treatment being developed by a drug maker or, more often, sold
for potentially hundreds of millions of dollars to another
pharma company.
That's leaving entire areas open
for the taking and Valeant — a
specialty pharma company that focuses on dermatology, ophthalmology and over-the-counter medications — which already has a strong foothold in emerging markets is poised to fill that void.
The environment
for deals among
specialty pharma companies like Jazz has heated up since the beginning of the year.
That's created quite a few opportunities
for value seekers, particularly in the
specialty pharma and biotech space.
So with the understanding that I sure as hell know what pervasive influence peddling can do to the process of peer review — because the
pharma companies do actively recruit their «key opinion leaders» on the basis of things like editorial clout and that prominence within their
specialty which gives them to hold responsibilities in peer review
for «high impact» medical journals — you might appreciate why, when I got to read those e-mails in the FOI2009.zip archive last November, my immediate desire was
for something brutally Sicilian to happen immediately and with spatter marks on the surrounding walls to the C.R.U. correspondents who had been concerting to infest and pervert the peer review process throughout the physical sciences wherever anything critical of the AGW hypothesis might be brought into publication.
Galenica Group recently announced that it has entered into a definitive agreement to acquire the US company Relypsa, Inc., (NASDAQ: RLYP), further strengthening its Business unit Vifor
Pharma by gaining full global rights to the potassium binder Veltassa ® (patiromer)
for oral suspension and enhancing its growing position as a global
specialty pharmaceutical company.
Together,
pharma and
specialty pharma professionals accounted
for 24 % of the survey respondents.
However, only 11 % of
pharma or
specialty pharma respondents report that they work
for a distributor.
An ability to embrace technology can go hand - in - hand with the perception that you are up
for the task of killing it in the world of complex
specialty pharma sales or medical device sales.
At $ 110,965 and $ 119,414, the average total incomes
for those working in
pharma and
specialty pharma are on the lower side of the spectrum.